Nexalin Technology Announces Publication Of Fourth Peer-Reviewed Article Reporting Results From Clinical Research On 15 mA DIFS Technology In Alzheimer's Disease

Results from the randomized, double-blind, sham-controlled TRANSFORM-AD study published in the Journal of Alzheimer's Disease, a recognized international peer-reviewed journal

Statistically significant improvement in sleep quality versus sham (p < 0.001) with no serious adverse events; authors describe the study as the first to evaluate high-intensity stimulation for neuropsychiatric symptoms in Alzheimer's disease

HOUSTON, TX, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NASDAQ:NXL) (the "Company" or "Nexalin"), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the publication of a fourth peer-reviewed article reporting results from clinical research on its 15 mA DIFS™ technology in Alzheimer's disease. The new analysis, published in the Journal of Alzheimer's Disease, found that 15 mA, 40 Hz stimulation delivered with Nexalin's device significantly improved sleep quality in patients with mild Alzheimer's disease compared with sham treatment, with no serious adverse events.